Secukinumab in the Treatment of Noninfectious Uveitis

We read with interest the article by Dick et al on the efficacy and safety of different doses of secukinumab in patients with noninfectious uveitis in 3 multicenter, randomized, double-masked, placebo-controlled, dose-ranging, phase III studies in the United States. Although the study suggested secukinumab had a beneficial effect in reducing the use of concomitant immunosuppressive medication, the researchers did not discover any differences in uveitis recurrence between the secukinumab treatment groups and placebo groups. The studies' authors believed that the relatively small sample size, the differences in the severity of the (Read more...)

Full Story →